Navigation Links
Driven by Sales of Lyrica, Cymbalta/Xeristar and Savella, the Fibromyalgia Drug Market Will Experience 4.2 Percent Annual Growth Through 2018

BURLINGTON, Mass., Sept. 8 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that increasing use of U.S. regulatory-approved agents -- Pfizer's Lyrica (pregabalin), Eli Lilly/Boehringer Ingelheim's Cymbalta/Xeristar (duloxetine) and Forest Laboratories' Savella (milnacipran) -- will drive 4.2 percent annual growth in the fibromyalgia drug market from 2009 to 2018. However, owing to the generic entry of sales-leading pregabalin, the market will decline sharply from $1.8 billion in 2018 to only $1.4 billion in 2019 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

The Pharmacor 2010 findings from the topic entitled Fibromyalgia reveal that an expanding drug-treated population, resulting from increasing diagnosis rates, will fuel annual market growth over the next several years in the world's major pharmaceutical markets. While the United States will account for more than two-thirds of major-market fibromyalgia drug sales in 2019, market expansion in Europe and Japan will be constrained by a dearth of approved therapies, lower diagnosis rates and less widespread recognition of the disorder.

The findings also reveal that duloxetine is now in close competition with pregabalin for market-leading status in the United States.

"Although pregabalin was the U.S. patient- and market-share leader in 2009, patient share of duloxetine grew significantly last year," said Decision Resources Analyst Andrea Buurma. "Sales of duloxetine are not projected to surpass pregabalin sales during our forecast period, owing in large part to market entry of generic duloxetine in the United States in 2013; however, we do expect duloxetine to supplant pregabalin as the U.S. patient-share leader by 2015."

The Pharmacor 2010 findings also reveal that, in light of the recent recommendation by an FDA advisory committee against the approval of sodium oxybate (Jazz Pharmaceuticals/UCB's JZP-6) for fibromyalgia, Decision Resources forecasts that it is unlikely the FDA will approve this agent for the indication. However, if the FDA issues a complete response letter and Jazz Pharmaceuticals is ultimately able to address the concerns voiced by the panel -- such as additional safety and efficacy data and a stricter Risk Evaluation and Mitigation Strategy -- sodium oxybate could have the potential to launch as a fibromyalgia therapy by late 2013.

About Pharmacor 2010The newly redesigned Pharmacor advisory service offers clients in the biopharmaceutical industry the most up-to-date information available on commercially significant disease topics.

About Decision ResourcesDecision Resources ( is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.For more information, contact:Decision Resources, Inc.Christopher

SOURCE Decision Resources, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Increasing Potential for RIS-driven PACS Modules in Europe, Finds Frost & Sullivan
2. New Study Shows Meganuclease-Driven Targeted Integration Using Cellectis bioresearchs cGPS® CHO-K1 Kit to be Highly Efficient for Drug Discovery
3. GeneGo Releases Content and Tools From Industry-FDA Driven MetaTox Partnership Via ToxHunter(TM)
4. Energetiq Introduces Laser-Driven Light Sources for Biophysical Applications
5. The Cancer Pain Drug Market, Driven by the Continued Dominance of Opioids, Will Increase From $2.3 Billion in 2008 to $3.7 Billion in 2018
6. HealthMedias Strongest Single Quarter Results: Growth Driven by Product Enhancements, New Partnerships
7. PDHI Launches ConXus Rewards, Announces Partnership With Hallmark Insights to Support Incentive-Driven Wellness Programs
8. Reportlinker Adds Pharmaceutical Contract Sales Organizations (CSO) - Emerging Markets to Drive Growth but Talent Acquisition in Specialty Secondary Care Remains a Challenge
9. SCOLR Pharma, Inc. Signs Agreement with The Emerson Group to Provide Sales Support for Nutritional & OTC Products
10. Recession Leads to Sales Decline and Loss for Allied Healthcare Products in Fiscal 2010
11. Kewaunee Scientific Reports Sales and Earnings for First Quarter
Post Your Comments:
(Date:12/1/2015)... , Dec. 1, 2015  Athletic apparel ... founder have agreed to pay $1.35 million to ... advertised the company,s copper-infused compression clothing would relieve ... arthritis and other diseases. Tommie ... requires the company and its founder and chairman ...
(Date:12/1/2015)... 2015 Pharma Tech Outlook recently conducted a ... Data Management Solution Providers - 2015 .  After careful ... CEOs, CIOs, VCs, analysts, and the Pharma Tech Outlook ... top 10 clinical data management solution providers (check out ... and 36 respectively). --> ...
(Date:12/1/2015)... and PITTSBURGH , Dec. ... announced that it expects to be the first to ... funded by international donors, TLE400 (Tenofovir Disoproxyl Fumarate 300 ... for $99 per patient, per year. Mylan partnered with ... The significantly reduced price could generate savings of tens ...
Breaking Medicine Technology:
(Date:12/1/2015)... CA (PRWEB) , ... December 01, 2015 , ... ... States, today announced that its iconic bottle has won top honors in Beverage World ... The Company also announced that it has been selected as a 2015 U.S.A. ...
(Date:12/1/2015)... Houston, TX (PRWEB) , ... December 01, 2015 , ... ... owner of Vitenas Cosmetic Surgery, has been named by MedEsthetics magazine as the Best ... best of the best among the many elite aesthetic physicians honored by the industry ...
(Date:12/1/2015)... ... 01, 2015 , ... Speech and physical therapies are traditionally ... technologies and under the right circumstances, these practices can be merged. This ... to his or her therapeutic sessions, as well as gives the physical and ...
(Date:12/1/2015)... ... December 01, 2015 , ... Growth in medical payments per ... decreases in utilization of hospital and nonhospital care, according to a recent study by ... for Louisiana, 16th Edition , found medical payments per claim with more than seven ...
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... ... identification tests to continue the expansion of the company’s growing product line of ... for Chinook (Oncorhynchus tshawytscha) and Sockeye (Oncorhynchus nerka) – allow InstantLabs to offer ...
Breaking Medicine News(10 mins):